Literature DB >> 6140887

In vitro effect of benzodiazepines on polymorphonuclear leukocyte oxidative activity.

G Goldfarb, J Belghiti, H Gautero, P Boivin.   

Abstract

The effect of three benzodiazepine compounds, diazepam, flunitrazepam, and clorazepate, on oxidative activity of human polymorphonuclear leukocyte (PMN) was investigated. The oxidative activity of zymosan-stimulated PMN in the presence of three concentrations (10, 20, and 40 micrograms/ml) of these compounds was measured polarographically. In addition, zymosan-stimulated nitroblue tetrazolium (NBT) reduction was measured in the presence of various concentrations of flunitrazepam. All three compounds inhibited oxygen consumption of the PMN. The extent of inhibition was linear with respect to log-concentrations; oxygen consumption was reduced 50% for concentrations of diazepam, flunitrazepam, and clorazepate of 13 micrograms/ml, 56 micrograms/ml, and 285 micrograms/ml, respectively. In addition 30% and 100% inhibition of NBT reduction by flunitrazepam were observed at respective concentrations of 10 micrograms/ml and 60 micrograms/ml. The clinical relevance of these findings remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6140887     DOI: 10.1097/00000542-198401000-00011

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  2 in total

1.  The influence of intravenous anaesthetics on polymorphonuclear leukocyte function.

Authors:  W Krumholz; C Demel; S Jung; G Meuthen; G Hempelmann
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

2.  Anaesthetic impairment of immune function is mediated via GABA(A) receptors.

Authors:  Daniel W Wheeler; Andrew J Thompson; Federico Corletto; Jill Reckless; Justin C T Loke; Nicolas Lapaque; Andrew J Grant; Pietro Mastroeni; David J Grainger; Claire L Padgett; John A O'Brien; Nigel G A Miller; John Trowsdale; Sarah C R Lummis; David K Menon; John S Beech
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.